India Halts Coronavirus Vaccine's Late Stage Study

Serum Institute of India (SII) stated it has 'decided to halt ongoing clinical trials in India of the COVID-19 vaccine candidate AZD1222 until AstraZeneca restarts its own global trials of the vaccine, reported India Express on September 10, 2020. AstraZeneca announced it is currently evaluating this vaccine candidate's clinical efficacy.

Serum, the world’s largest vaccine manufacturer by volume (1.5 billion doses), previously announced on August 7, 2020, that it had entered into partnerships to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries.